Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1976 1
1977 1
1981 1
1983 2
1984 1
1987 1
1988 5
1989 4
1990 11
1991 5
1992 17
1993 14
1994 9
1995 11
1996 17
1997 16
1998 13
1999 16
2000 22
2001 25
2002 17
2003 20
2004 21
2005 18
2006 22
2007 17
2008 36
2009 33
2010 36
2011 48
2012 57
2013 47
2014 67
2015 63
2016 71
2017 101
2018 107
2019 148
2020 208
2021 245
2022 247
2023 282
2024 256
2025 307
2026 75

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,467 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, Antonuzzo L, Wiechno P, Atduev V, Kann AG, Kim TH, Suárez C, Chang CH, Roghmann F, Özgüroğlu M, Eigl BJ, Oliveira N, Buchler T, Gadot M, Zakharia Y, Armstrong J, Gupta A, Hois S, van der Heijden MS; NIAGARA Investigators. Powles T, et al. Among authors: vu tq. N Engl J Med. 2024 Nov 14;391(19):1773-1786. doi: 10.1056/NEJMoa2408154. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282910 Clinical Trial.
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
Antozzi C, Vu T, Ramchandren S, Nowak RJ, Farmakidis C, Bril V, De Bleecker J, Yang H, Minks E, Park JS, Grudniak M, Smilowski M, Sevilla T, Hoffmann S, Sivakumar K, Suzuki Y, Youssef E, Sanga P, Karcher K, Zhu Y, Sheehan JJ, Sun H; Vivacity-MG3 Study Group. Antozzi C, et al. Among authors: vu t. Lancet Neurol. 2025 Feb;24(2):105-116. doi: 10.1016/S1474-4422(24)00498-8. Lancet Neurol. 2025. PMID: 39862879 Clinical Trial.
Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy.
Gong L, Luo J, Yang E, Ru B, Qi Z, Yang Y, Rani A, Purohit A, Zhang Y, Guan G, Paul R, Vu T, Chen Z, Ji R, Day CP, Wu C, Merlino G, Fitzgerald D, Altan-Bonnet G, Aldape K, Wu J, Guan X, Jiang P. Gong L, et al. Among authors: vu t. Cell. 2025 Sep 4;188(18):5062-5080.e32. doi: 10.1016/j.cell.2025.07.004. Epub 2025 Jul 28. Cell. 2025. PMID: 40730154
CD5 deletion enhances the antitumor activity of adoptive T cell therapies.
Patel RP, Ghilardi G, Zhang Y, Chiang YH, Xie W, Guruprasad P, Kim KH, Chun I, Angelos MG, Pajarillo R, Hong SJ, Lee YG, Shestova O, Shaw C, Cohen I, Gupta A, Vu T, Qian D, Yang S, Nimmagadda A, Snook AE, Siciliano N, Rotolo A, Inamdar A, Harris J, Ugwuanyi O, Wang M, Carturan A, Paruzzo L, Chen L, Ballard HJ, Blanchard T, Xu C, Abdel-Mohsen M, Gabunia K, Wysocka M, Linette GP, Carreno B, Barrett DM, Teachey DT, Posey AD, Powell DJ Jr, Sauter CT, Pileri S, Pillai V, Scholler J, Rook AH, Schuster SJ, Barta SK, Porazzi P, Ruella M. Patel RP, et al. Among authors: vu t. Sci Immunol. 2024 Jul 19;9(97):eadn6509. doi: 10.1126/sciimmunol.adn6509. Epub 2024 Jul 19. Sci Immunol. 2024. PMID: 39028827 Free PMC article.
Current cell therapies for systemic lupus erythematosus.
Dao LTM, Vu TT, Nguyen QT, Hoang VT, Nguyen TL. Dao LTM, et al. Among authors: vu tt. Stem Cells Transl Med. 2024 Sep 10;13(9):859-872. doi: 10.1093/stcltm/szae044. Stem Cells Transl Med. 2024. PMID: 38920310 Free PMC article. Review.
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).
Howard JF Jr, Vu T, Li G, Korobko D, Smilowski M, Liu L, Gistelinck F, Steeland S, Noukens J, Van Hoorick B, Podhorna J, Borgions F, Li Y, Utsugisawa K, Wiendl H, De Bleecker JL, Mantegazza R; ADAPT-SC and ADAPT-SC+ Study Groups. Howard JF Jr, et al. Among authors: vu t. Neurotherapeutics. 2024 Sep;21(5):e00378. doi: 10.1016/j.neurot.2024.e00378. Epub 2024 Sep 2. Neurotherapeutics. 2024. PMID: 39227284 Free PMC article. Clinical Trial.
Reply.
Tiruneh SA, Vu TTT, Moran LJ, Callander EJ, Allotey J, Thangaratinam S, Rolnik DL, Teede HJ, Wang R, Enticott J. Tiruneh SA, et al. Among authors: vu ttt. Ultrasound Obstet Gynecol. 2025 Jul;66(1):110-111. doi: 10.1002/uog.29253. Epub 2025 May 29. Ultrasound Obstet Gynecol. 2025. PMID: 40439136 No abstract available.
Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension.
Vu TH, Mantegazza R, Annane D, Katsuno M, Meisel A, Nicolle MW, Bril V, Aguzzi R, Frick G, Howard JF Jr; CHAMPION MG Study Group. Vu TH, et al. Eur J Neurol. 2025 Apr;32(4):e70158. doi: 10.1111/ene.70158. Eur J Neurol. 2025. PMID: 40241307 Free PMC article. Clinical Trial.
2,467 results